BioNTech's Founders Hand Over the Keys Just as Gotistobart Delivers Its Strongest Data Yet
Published on 09/24/2026 at 03:30 | Editorial boerse-global.de
BioNTech is asking its shareholders to believe two things at once: that its cancer pipeline is finally producing the kind of evidence that justifies the long wait, and that the departure of the two scientists who built the company is a managed transition rather than a warning sign. The market, for now, is hedging its bets.
The stock closed Wednesday at EUR 86.60, a decline of 1.7% on the day, though it remains up 6.5% since the start of the year. That muted reaction captures the tension running through the Mainz-based biotech: ample liquidity keeps the shares from steep falls, but fresh upside now depends almost entirely on what happens in the laboratory.
A Founder Exit That Was Anything but Abrupt
Word that U?ur ?ahin and Özlem Türeci are stepping back from their leadership roles has dominated the conversation. By the end of this year at the latest, both will relinquish their operational posts in Mainz. The two are pouring their energies into a new venture, Arife SE, registered as a European stock corporation headquartered in Mainz with share capital of EUR 120,000. The company will focus on developing, manufacturing and commercializing next-generation mRNA therapies.
Crucially for BioNTech investors, the old and new companies remain tightly linked. BioNTech is contributing existing rights and technologies to the new entity and, in return, securing a minority stake, alongside contractually agreed milestone payments and royalties. Should ?ahin and Türeci strike gold in their new laboratory, BioNTech participates directly through that holding and future licensing income. The arrangement also spares the parent company the cost and risk of early-stage experimentation. Michael Maximilian Kring, a former BioNTech finance chief, is set to take charge of Arife's finances.
Should investors sell immediately? Or is it worth buying BioNTech?
The handover at the top follows a deliberate path. Guido Oelkers will assume the role of chief executive no later than February 1, 2027, while a successor to Türeci as chief medical officer has yet to be named. Both founders will stay on as shareholders, but day-to-day control passes to new hands. The shift says plainly that BioNTech is completing its evolution from a research-driven biotech pioneer into a commercially oriented oncology and pharmaceutical group, with Oelkers expected to emphasize late-stage trials, approvals and sales infrastructure.
Gotistobart Posts a Survival Gap That Demands Attention
Against that backdrop of institutional change, the clinical story has taken a decisive turn. On September 14, BioNTech reported encouraging Phase 3 results for its investigational drug Gotistobart. In the PRESERVE-003 trial, the antibody achieved a median overall survival of 18.5 months in previously treated squamous non-small cell lung cancer, compared with just 10.0 months for standard chemotherapy.
The benefit applies to patients whose disease had progressed after prior immunotherapy and chemotherapy—a group with few remaining treatment options. The statistics back up the finding: a hazard ratio of 0.56 and a nominal p-value of 0.0295. BioNTech presented the data alongside OncoC4 at the IASLC 2026 World Conference on Lung Cancer just over a week ago, and the shares have climbed 3.4% since.
A Pipeline That Giveth and Taketh Away
The Gotistobart readout demonstrates that BioNTech's pipeline can generate substantial data. Yet the path to approval remains lengthy and requires further regulatory steps. Setbacks are part of the terrain: roughly two weeks ago, the company halted its Cevumeran study in colorectal cancer. The stock has actually gained 1.9% since that disclosure, but the episode laid bare how fragile clinical expectations can be. In oncology, trial terminations are routine, since many mechanisms only reveal their limits once tested in patients. What matters for observers is whether other candidates in parallel can deliver robust signals—and Gotistobart, for now, is doing exactly that.
BioNTech at a turning point? This analysis reveals what investors need to know now.
What the Market Is Still Waiting For
Sentiment remains unsettled. The shares changed hands at EUR 87.65 on the day the founder exit became clear, a modest 0.5% decline, as investors struggled to price the company's innovative potential without its two most visible figureheads. On the charts, the picture is mixed: the stock has recovered from its low, but sits 17% below its 52-week high, lacking a clear catalyst to push higher.
The founders' decision is, in the end, a logical one. Top researchers chafe against rigid corporate structures once a company is managing billions in revenue. By spinning experimental mRNA concepts into Arife SE, ?ahin and Türeci regain the agility that early-stage science demands. For BioNTech shareholders, the situation is far from hopeless—the minority stake and milestone agreements protect the parent's interests. But investors must accept that BioNTech has entered a new chapter, one in which visionary founders give way to sober management charged with delivering a single thing above all: viable products from its own clinical pipeline.
Ad
BioNTech Stock: New Analysis - 24 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
